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Dengue virus (DENV) is a mosquito-borne virus belonging to the Flaviviridae family. There are 4
serotypes of DENV that cause human disease through transmission by mosquito vectors. DENV
infection results in a broad spectrum of clinical symptoms, ranging from mild fever to dengue
hemorrhagic fever (DHF), the latter of which can progress to dengue shock syndrome (DSS) and
death. Researchers have made unremitting efforts over the last half-century to understand DHF
pathogenesis. DHF is probably caused by multiple factors, such as virus-specific antibodies, viral
antigens and host immune responses. This review summarizes the current progress of studies on
DHF pathogenesis, which may provide important information for achieving effective control of
dengue in the future.
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INTRODUCTION
Dengue virus (DENV) is a mosquito-borne virus belong-
ing to the Flaviviridae family. There are 4 serotypes of
DENV (DENV-1 through DENV-4) that cause human
disease through transmission via the mosquito vectors
Aedes aegypti and Aedes albopictus (Gubler, 2011).
There are more than 100 dengue-epidemic countries in
the world. Furthermore, approximately 2.5 billion people
are at risk of dengue infection every year. It estimated
390 million dengue infections per year, of which 96 mil-
lion manifest apparently any level of disease severity
(Bhatt et al., 2013). In 2015, 2.35 million cases of dengue
were reported in America alone, and more than ten thou-
sand of these cases involved severe hemorrhagic-related
clinical symptoms. Dengue infection remains an impor-
tant threat to public health and is responsible for a large
global disease burden.
Most DENV infections are asymptomatic or present a
mild illness with flu-like symptoms, such as fever, head-
ache, myalgia and decreased platelet counts and leu-
copenia. These symptoms are known as dengue fever
(DF), which is an acute, self-limited, febrile illness. How-
ever, some DF patients develop a severe syndrome known
as Dengue Hemorrhagic Fever (DHF), in which patients
may display hematomas with marked thrombocytopenia
or extremely low platelet counts. Even more severe clin-
ical symptoms are produced when DENV infection de-
velops Dengue Shock Syndrome (DSS), a disease similar
to DHF that additionally includes coagulation abnormal-
ities, increased vascular fragility, raised plasma leakage/
heme concentration, loss of fluid due to capillary per-
meability that may progress to hypovolemic shock, and
increased risk of multi-organ failure (WHO/TDR,
2009). The clinical hallmark of DHF is plasma leakage,
which usually lasts for approximately 48 hours and leads
to reduced circulatory volume (Srikiatkhachorn, 2009).
Bleeding is common following dengue infection, how-
ever it is more frequent in DHF/DSS than in DF. Most
dengue-associated deaths result from the symptoms asso-
ciated with DHF/DSS (Hermann et al., 2015). There is
no antiviral therapy against DENV infection. Dengvaxia,
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a commercial vaccine developed by Sanofi Pasteur, was
licensed in several dengue-endemic countries (Hladish et
al., 2016; Recker et al., 2016). DHF is the most life-
threatening consequence of DENV infection. Previous
studies have suggested that both viral and host factors
might contribute to the pathogenesis of this disease, in-
cluding Nonstructural protein 1 (NS1) viral antigen and
its antibodies, virus variation and virulence, subgenomic
RNA, antibody-dependent enhancement (ADE), and the
presence of memory cross-reactive T cells. The further
research on the pathogenesis of DHF can provide a new
target for the prevention and control of dengue infec-
tious diseases.
ROLE OF DENV NONSTRUCTURAL PROTEIN-1
(NS-1) AND ITS ANTIBODIES IN DHF
PATHOGENESIS
NS1, a nonstructural protein encoded by DENV, is ex-
pressed in multiple oligomeric forms and is present in a
variety of cellular locations, including on intracellular
membranes, at the cell surface and extracellularly as a
soluble, secreted lipoparticle (Chuang et al., 2016). Dur-
ing acute DENV infection, secreted NS1 protein is pre-
sent in patient sera at high levels (Libraty et al., 2002),
which might correlate with disease severity and contri-
bute to the pathogenesis of DHF in a host (Chuang et al.,
2013; Srikiatkhachorn and Kelley, 2014). Indeed, DENV
NS1 might directly bind to the surfaces of host cells to
cause tissue damage (Avirutnan et al., 2007; Beatty et al.,
2015; Modhiran et al., 2015). A recent study suggested
that DENV NS1 elicits inflammatory cytokine produc-
tion by activating macrophages and human peripheral
blood mononuclear cells (PBMCs) through Toll-like re-
ceptor 4 (TLR4), thus leading to disruption of endothelial
cell monolayer integrity in blood vessels (Modhiran et
al., 2015). Moreover, DENV NS1 might also trigger
complement activation, causing plasma leakage (Kurosu
et al., 2007). During this process, soluble DENV NS1 is
released from infected cells and independently activates
complement factors present in the fluid phase (Nielsen,
2009). A close correlation has been found between
DENV NS1 concentration and C5b-C9 complex forma-
tion. The C5b-C9 complex can stimulate robust expres-
sion of inflammatory cytokines that are associated with
DHF development (Suresh et al., 2016). Recently, it has
been reported that DENV NS1 may induce autophagy in
the HMEC-1 human endothelial cell line as well as in
mice, and that this autophagy is mediated by NS1-asso-
ciated secretion of a macrophage migration inhibitory factor
(MIF) (Chen et al., 2016).
In addition to the NS1 protein itself, NS1 antibodies
might also contribute to DHF pathogenesis. For example,
the binding of anti-NS1 antibodies to GPI-anchored NS1
proteins on cell membranes can activate cellular signal
transduction pathways, leading to protein tyrosine phos-
phorylation, which may enhance DENV replication within
infected cells (Jacobs et al., 2000). Moreover, protein
phosphorylation and NF-κB activation have been ob-
served after stimulating human HMEC-1 cells with anti-
DENV NS1 antibodies. Furthermore, the expression of
several cytokines and chemokines, such as IL-6, IL-8,
and MCP-1, is increased after treatment of endothelial
cells with anti-DENV NS1 antibodies, suggesting that
DENV NS1 antibodies can stimulate the release of mul-
tiple inflammatory factors in an NF-κB-dependent man-
ner (Lin et al., 2005). Disordered release of cytokines is
considered as a major factor underlying DHF pathogen-
esis. Therefore, NS1 antibody-mediated activation of im-
mune responses may play an important role in the devel-
opment of Dengue-mediated thrombocytopenia and vas-
cular leakage during the critical phase of DHF/DSS.
Recently, the induction of autoimmune disorders by
anti-NS1 antibodies has also been described as a contri-
buting factor to DHF pathogenesis. Because there is se-
quence homology between DENV NS1 and several self-
antigens, such as plasminogen and integrin, proteins on
human endothelial and platelet cells, auto-antibodies in-
duced by NS1 may cross-react with these self-antigens
(Falconar, 1997; Liu et al., 2016; Rachman et al., 2013;
Chuang et al., 2016). These reactions stimulate nitric ox-
ide (NO) expression and cell apoptosis in endothelial
cells and cause cell lysis and inhibition of aggregation in
platelets (Sun et al., 2007). Damage to endothelial cells
and platelets may contribute to thrombocytopenia, co-
agulopathy and vascular leakage in DHF (Sun et al.,
2007; Wan et al., 2014).
ROLE OF DENV GENOME IN DHF
PATHOGENESIS
Genetic differences among DENV genotypes are asso-
ciated with differential viral virulence that may contribute
to the development of the severe diseases, such as DHF
and DSS (Ubol et al., 2008; Mammen et al., 2014). Some
DENV genotypes have greater virulence and epidemic
potential than others. This viewpoint was primarily intro-
duced based on epidemiological observations (Gubler et
al., 1981). In the American Dengue outbreak that oc-
curred in 1981, a Southeast Asian DENV-2 genotype
emerged more virulent than the indigenous American
genotype (Rico-Hesse et al., 1997; Rico-Hesse et al.,
1998). Indeed, evidence has indicated that a South-
eastern Asian DENV-2 genotype virus replicate at higher
titers than an American genotype virus in both humans and
mosquitoes (Anderson and Rico-Hesse, 2006; Vasilakis
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et al., 2007). Besides, the intra-serotype evolution of epi-
demic DENV strains might be another cause of increas-
ing viral virulence. The clinical manifestations and case-
fatality rates of DHF typically increase during the later
periods of epidemics, a phenomenon that was observed
in the Cuban epidemics of 1981 and 1997, the Towns-
ville, Australia epidemic of 1992, and the Oaxaca, Mex-
ico epidemic of 2005 (Guzman et al., 2000; Martina et
al., 2009; Ritchie et al., 2013). An analysis of DENV
genomes suggested that circulating DENV might evolve
greater virulence through passage in patients during an
epidemic (Chen et al., 2008). Thus, variations in the
DENV genome serve to determine viral infectivity in
both hosts and vectors (Ritchie et al., 2013).
Besides the genome variation, the subgenomic flavi-
virus RNA (sfRNA) may play a role in DENV replica-
tion in host cells, thus contributing to DHF pathogenesis.
During DENV replication, a 11 kb RNA genome may be
incompletely degraded from their 3’ untranslated region
(UTR) by host exoribonuclease to generate a 0.3 to 0.5
kb small RNA termed sfRNA (Pijlman et al., 2008; Funk
et al., 2010; Chapman et al., 2014; Roby et al., 2014).
sfRNA may accumulate in the infected cells to suppress
the host antiviral immune responses, such as type I inter-
feron signaling (Manokaran et al., 2015; Chang et al.,
2013). sfRNA may also facilitate DENV replication
through altering host mRNA stability (Moon et al., 2012;
Schnettler et al., 2012), thereby acting as a player in
DENV immune evasion and DHF pathogenesis.
ROLE OF ANTIBODY-DEPENDENT
ENHANCEMENT (ADE) IN DHF PATHOGENESIS
Epidemiological evidence has shown that increased
risk for DHF/DSS is associated with a secondary infec-
tion from a different DENV serotype than that causing
the initial infection (Guzman et al., 2013). Data gathered
from Cuba, Hawaii and Thailand have shown that indi-
viduals with circulating DENV 1 antibodies are at an en-
hanced risk for acquiring DHF during subsequent DENV
2 or DENV 3 infections (Alvarez et al., 2006). Further-
more, an infant infected with a DENV serotype that is
different from the serotype that its infected mother is at
an increased risk for DHF/DSS (Halstead et al., 2002).
Based on assessments of hospital patients, the incidence
of DHF/DSS during primary dengue infections was 11 to
Figure 1. The mechanisms involved in DHF pathogenesis include nonstructural protein 1 (NS1) viral antigen and its anti-
bodies, virus genome variation, sfRNA, antibody-dependent enhancement (ADE), and the presence of memory cross-
reactive T cells. NS1 and its antibodies contribute to DHF pathogenesis by triggering complement activation and then
eliciting inflammatory cytokine production, inducing autophagy in endothelial cell, enhancing DENV replication, inducing
autoimmune disorders; DENV genome variation evolve greater virulence, and sfRNA induce the enhancement of viral
replication; FcγR-mediated ADE can enhance viral replication and trigger cytokines and chemokines release; Activated
DENV-specific cross-reactive T cells promote the release of cytokines and chemokines, and T cell apoptosis also con-
tributes to DHF pathogenesis.
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12 per 1000 compared with 118 to 208 per 1000 during
secondary dengue infections (Guzman et al., 2013). The
risk of developing DHF during a secondary infection is
at least 10-fold greater than the risk of developing the
condition during a primary infection (Srikiatkhachorn,
2009). This increased infection rate is caused by anti-
bodies induced from the first infection and has been
termed antibody-dependent enhancement (Halstead,
1970). Indeed, the ADE phenomenon has been re-
peatedly demonstrated in DENV infections of cell cul-
tures and animals. When DENV is incubated with di-
luted anti-DENV sera or DENV-specific antibodies, viral
replication in human monocytes and some cell lines is
significantly promoted. Passive immunization with
DENV antibodies/antisera prior to virus inoculation in
rhesus monkeys enhanced viral replication more than
100-fold over control animals (Goncalvez et al., 2007;
Sasaki et al., 2013; Chaichana et al., 2014; Martinez
gomez et al., 2016). Nonetheless, not all cases of DHF/
DSS are associated with ADE. Evidence from a phase 3
clinical trial of a Dengue vaccine (Sanofi Pasteur) found
no evidence of ADE generation in the study population
(Sabchareon et al., 2012). Although ADE has been
primarily described in relation to DENV infection, the
phenomenon has also been associated with several other
viral species based on in vitro enhancements of infection
(Takada et al., 2003; Martina et al., 2009; Chan-Hui and
Swiderek, 2016).
Previous studies have demonstrated that ADE are di-
rected toward anti-E antibodies and anti-prM antibodies.
Although more studies have been designed to evaluate
the role of E protein, prM have attracted more attention
since 2010, when it was first proposed that anti-prM anti-
bodies involved in the ADE phenomenon (Dejnirattisai
et al., 2010). Several groups have shown that anti-prM
MAbs exhibit ADE properties in cell culture and in ani-
mal models of DENV infection (Smith et al., 2012; Luo
et al., 2013). Thus, anti-prM antibodies are likely to play
an important role in the pathogenesis of DHF in humans.
The mechanism of ADE remains only partially under-
stood. Fcγ receptor (FcγR)-mediated uptake of virion-
antibody complexes into permissive cells may be one ex-
planation for the enhancement of DENV infection (Sato
et al., 2015). FcγR is a multi-subunit complex that is dis-
tributed on the surfaces of many types of immune cells,
such as dendritic cells, macrophages and mast cells, and
recognizes the Fc regions of immunoglobulins. During
DENV infection, antibodies with infection-enhancing
activity are generated and subsequently form virion-anti-
body complexes. These complexes can rapidly internal-
ize into FcγR-bearing cells via interactions with FcγR,
which results in a higher number of infected cells in the
presence versus the absence of antibodies (Halstead,
1982). Moreover, previous studies have also shown that
FcγR-mediated DENV infection might enhance viral rep-
lication through suppression of intracellular antiviral in-
nate immune responses, including interferon-mediated
antiviral responses, and enhancement of IL-10 produc-
tion in DENV-infected cells. The suppression of host im-
mune responses may promote the production of high
numbers of infectious DENV virions (Ubol and Halstead,
2010).
The clinical manifestations of DHF include endothelial
cell damage, enhancement of vascular permeability,
plasma leakage and liver injury (Halstead and Cohen,
2015). However, these manifestations may be not neces-
sarily a direct result of cell death induced by DENV rep-
lication because viral load peaks during the febrile phase
and rapidly declines by the time hemorrhagic fever and
plasma leakage develop. In addition to enhancing viral
entry, FcγR-mediated ADE directly triggers robust re-
lease of cytokines from mast cells and other immune
cells, which may mediate vascular endothelial cell dys-
function and increase vascular permeability. The release
of cytokines is considered a key factor that contributes to
DHF pathogenesis (King et al., 2002; Brown et al., 2011).
ROLE OF T CELLS IN DHF PATHOGENESIS
The increases in cytokine production and CD8+ T cell
activation that have been observed in severe dengue pa-
tients imply that cross-reactive T cells have a role in me-
diating the pathogenesis of DHF (Mathew and Rothman,
2008). Memory T-cells from the primary infection were
activated by a heterologous virus during second infec-
tion, and showed highly cross-reactivity and low affinity
leading to inefficiency at killing infected cells and clear-
ing the newly infective virus serotype. On the contrary,
cross-reactive T cell contribute to DHF occurrence by
substantial immunopathology. DHF patients have been
reported to demonstrate enhanced circulation of cy-
tokines and chemokines, IFN-γ, IL-2 and TNF-α pro-
duced by activated DENV-specific cross-reactive T cells,
compared to DF patients (Bozza et al., 2008; Malavige et
al., 2012; Kurane et al., 2011), suggesting a positive cor-
relation between cross-reactive T cell activation and the
severity of dengue-associated disease. Furthermore, T
cell apoptosis in DHF patients contributes to the severity
of dengue-associated disease (Jaiyen et al., 2009;
Midgley et al., 2011; Malavige et al., 2012). A previous
study reported that the immunosuppressive cytokine IL-
10 could lead to T cell apoptosis in patients with acute
dengue infection. IL-10 concentrations are elevated in
the sera of patients with severe dengue (Mathew and
Rothman, 2008). IL-10 blockade has been significantly
associated with reduced T cell apoptosis in acute DENV
infections. In agreement, reduced T cell numbers have
Progress towards pathogenesis of DHF
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been found in DHF patients compared to DF patients
(Green et al., 1999), suggesting that T cell apoptosis
reduces viral clearance and consequently results in an
impaired antiviral response, leading to severe clinical
dengue diseases.
CONCLUSION
Clinicians and scientists have increasingly focused on
understanding the pathogenesis of DHF from several
perspectives; however, the mechanisms underlying this
pathogenesis are not yet fully elucidated. Further studies
are urgently required to improve our understanding of
DHF pathogenesis, which is important for developing ef-
fective therapeutics for and vaccine strategies against
DENV infection.
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